Harnessing the Evidence: Implementing NCPA and NABP’s PhARM-OUD Guidelines to Improve Access To Buprenorphine in Your Pharmacy
Sponsored by the Foundation for Opioid Response Efforts
Nov. 14, 2 p.m. ET
Buprenorphine is the only agonist medication for opioid use disorder that can be dispensed in all community in the United States. With the passage of the Mainstreaming Addiction Treatment Act in late 2022, any DEA-licensed prescriber can now prescribe buprenorphine for the treatment of OUD. This landmark legislation promises to extend access to buprenorphine; still, only around half of all pharmacies in the United States stock buprenorphine.
In this session, Tyler Varisco, PharmD, PhD, will review the evidence supporting the safe and effective use of buprenorphine before reviewing the creation of the PhARM-OUD Guideline and implementing its recommendations in practice.
CE Webinar Archive
Miss a prior CE Webinar? Visit ncpa.org/learn to find our entire catalog of on Demand CE course offerings